Navigation Links
Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
Date:12/16/2009

0614.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene (CELG) http://www.celgene.com, Geron (GERN) http://www.geron.com, and Human Genome Sciences (HGSI) http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit

SOURCE Wound Management Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
2. Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
3. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
4. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
5. Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial
6. Wound Management Technologies, Inc. Announces Evidence Based Study
7. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
8. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
9. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
10. New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds
11. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
(Date:5/23/2013)... , May 23, 2013  Spring Bank Pharmaceuticals, ... treatment of viral infections, today announced that it has ... 9200, its investigational, once daily, oral therapy for the ... healthy, HCV-infected patients and is designed to assess both ... 9200 is a first-in-class drug for the treatment of ...
(Date:5/23/2013)... 2013   Direct to implant, or "one ... appropriate option for many women with BRCA (BReast ... breast cancer risk, or with breast cancer. Traditionally, ... a second surgery to insert permanent implants, but ... as mastectomy can be a medically and cosmetically ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3
... , , , , , , ... MIVI-TRUST Phase III Program With Microplasmin Recruits a Total of Over,640 ... (Euronext Brussels: THR), a biopharmaceutical company,focused on the discovery and development ... that it has completed,the enrolment of the second Phase III trial ...
... , NORCROSS, Ga., Dec. 15 Immucor, Inc. (Nasdaq: ... to the blood transfusion industry, today announced that it will ... 6, 2010 after the market close. The Company will host ... a.m. (Eastern Time) to discuss the results. , ...
Cached Medicine Technology:ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4
(Date:5/23/2013)... A medical malpractice case which was filed ... by Lori Mandel, an office manager in her 50’s, ... Ms. Mandel sought the medical expertise of an ... that affected the quality of her life and her ... that her doctor rendered conservative treatment for 2 years, ...
(Date:5/23/2013)... International Science Consortium, Ltd., issued the following statement ... 2013: , Reform of chemical safety legislation will ... , Ensuring the safety and appropriate use ... the EPA,s Toxic Substances Control Act is a ... vision for transforming toxicity testing "from a system ...
(Date:5/23/2013)... in imaging of brain activity developed by Jean ... and his colleagues lead to improved treatment of ... electroencephalogram (EEG) and functional magnetic resonance imaging (fMRI) ... generating epileptic seizures, giving neurosurgeons a better understanding ... These results were presented at the 2013 ...
(Date:5/23/2013)... Bronson Gray HealthDay Reporter , , WEDNESDAY, May 22 ... device used to save an infant born with a serious ... marriage of bioengineering and surgery. A report in the ... the situation that sparked the innovation. At first, the ... began to have difficulty breathing and eating when he was ...
(Date:5/23/2013)... According to a new market report "Service Delivery ... Management (SDM); Telecom Application Server; Service Creation Environment; Orchestration ... published by MarketsandMarkets, the SDP Market is expected to ... 9.15% from 2013 to 2018. , Browse:, ... 84 Figures , 189 Pages and an ...
Breaking Medicine News(10 mins):Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 2Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 3Health News:New imaging techniques used to help patients suffering from epilepsy 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 3Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3
... , ENGLEWOOD, Colo., Aug. 10 Baxa, ... and administration of fluid medications, announces the launch of a ... and medication safety practices. The Culture of Safety Page, ... share experiences, insights and ideas for improving their profession and ...
... Aug. 10 /PRNewswire-Asia/ -- China Medicine Corporation,(OTC Bulletin ... leading,developer and distributor of prescription and over the ... supplements, and,medical devices and medical formulations, today announced ... a.m. Eastern Time on Thursday, August 13, 2009, ...
... , SAN FRANCISCO, Aug. 10 ... Mark Gastineau to senior vice president and chief executive of ... Unit (ISGBU). Gastineau joined Blue Shield in 2006 as ... underwriting and compliance areas in developing strategies to increase membership ...
... ... and school administrators will help U.S. schools meet growing needs of students with autism ... ... Society announced the publication of professional competencies for teaching students with autism spectrum disorders ...
... , , NEW YORK, Aug. 10 ... letter of intent to form ZiRx Therapeutics, Ltd., a joint venture that ... cell proteins with drugs that potentially block or stop the spread of ... to broad spectrum antiviral drugs as well as drugs that are less ...
... YORK, Aug. 10 In an unprecedented meeting at the UN, ... and currently an opposition leader and human rights protagonist for Iran, ... violations of human rights by the regime in Iran. , ... Secretary General for his June 22 statement of urgent concern over ...
Cached Medicine News:Health News:Baxa Corporation Launches 'Culture of Safety' Facebook Page 2Health News:Baxa Corporation Launches 'Culture of Safety' Facebook Page 3Health News:China Medicine Announces Conference Call to Discuss Second Quarter 2009 Results 2Health News:Mark Gastineau Named Senior Vice President of Individual, Small Group, and Government Business Unit at Blue Shield of California 2Health News:New National Professional Competencies for Teachers of Autism Released by Leaders in the Field 2Health News:New National Professional Competencies for Teachers of Autism Released by Leaders in the Field 3Health News:Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd. 2Health News:Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd. 3Health News:Former UN Human Rights Rapporteur Offers 7 Points of Action on Iran to the UN Secretary General 2
...
...
The AGC Revision Knee, extends the AGC Family to include implants for severe primary knees or revision. Provides rotational freedom of +/- 2 and varus/valgus freedom of +/- 1.5....
The Performance Knee System is a wide and easy to use system that offers enough options to cover any indication for primary and revision knee surgery, and all this with extensive intraoperative flexi...
Medicine Products: